Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-thio-2'-deoxyguanosine + cemiplimab
- Development stage
- Unknown
- Lead developer
- Maia Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug is an experimental **combination therapy** consisting of **6-thio-2'-deoxyguanosine** (6-thio-dG), a small molecule telomerase substrate that induces telomere dysfunction and cancer cell death, and **cemiplimab** (brand name Libtayo), a fully human monoclonal antibody that blocks PD-1 (programmed death receptor-1) to enhance antitumor T-cell immune responses. 6-thio-2'-deoxyguanosine targets cancer cell telomeres, while cemiplimab provides immune checkpoint inhibition. This combination is being investigated for synergistic antineoplastic activity, particularly in solid tumors resistant to traditional therapy.
- Brand names
- Libtayo
- Other names
- 6-thio-2'-deoxyguanosine6-thio-dGcemiplimabcemiplimab-rwlc
02
Targets
TERT (Telomerase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on 6-thio-2'-deoxyguanosine + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-thio-2'-deoxyguanosine + cemiplimab.